Buy SYNVISC®

SYNVISC® is a hyaluronic acid-based viscosupplement used to treat osteoarthritis-related knee pain. It consists of hylan A and B polymers, derived from a highly purified bacterial fermentation process, which closely resemble the natural synovial fluid found in healthy joints.

Upon intra-articular injection, SYNVISC® restores the viscoelasticity of synovial fluid, enabling smoother joint movement and effective shock absorption. It reduces mechanical stress on the cartilage and minimizes pain through improved lubrication, enhancing overall joint function without systemic drug intervention.

SYNVISC® is indicated for the treatment of pain in osteoarthritis of the knee in patients who have not responded to conservative, non-pharmacologic therapy and simple analgesics. It is used to:

• Lubricate and cushion the knee joint 
• Improve mobility in osteoarthritis patients 
• Reduce dependency on oral NSAIDs 
• Delay surgical intervention for joint replacement 

SYNVISC® supports the joint environment, particularly when endogenous hyaluronic acid levels are depleted.

SYNVISC® is one of the most extensively studied viscosupplements on the market, with a long history of global use. Its unique formulation and dual-polymer structure deliver extended joint protection and improved mobility for osteoarthritis patients.

Key benefits include:

• Non-animal origin hyaluronic acid 
• Clinically proven pain relief lasting up to six months 
• Excellent safety profile with minimal side effects 
• Used in over 60 countries with decades of clinical experience 
• Offered in multiple formats for flexible treatment planning 

Healthcare providers who buy SYNVISC rely on its consistent performance, safety, and global regulatory approvals.

Patients typically experience relief within a few weeks of the initial injection, with peak results emerging between 4 to 6 weeks post-treatment. The effects of a SYNVISC® injection may last up to six months, depending on the severity of osteoarthritis and patient activity levels.

Repeat treatments can be administered based on clinical evaluation.

SYNVISC® has a strong safety profile. Its high-purity, non-animal derived formulation reduces immunogenic risks and adverse reactions.

When administered under sterile conditions by trained professionals, SYNVISC® is well tolerated. Most side effects are mild and transient.